Search

Supplemental material, sj-docx-1-tag-10.1177_17562848221137430 for Risk of prostate cancer in patients with inflammatory bowel disease: a nationwide cohort study in South Korea by Ji Eun Na, Tae Jun Kim, Yeong Chan Lee, Ji Eun Kim, Eun Ran Kim, Sung Noh Hong, Dong Kyung Chang and Young-Ho Kim in Therapeutic Advances in Gastroenterology

Clinical decision support tools (CDST) were developed to predict drug response to various biological treatments for Crohn’s disease (CD). This study investigated whether CDSTs for vedolizumab (V-CDST) and ustekinumab (U-CDST) can be used as prognostic or drug-specific markers to predict response. A hypothetical scenario involving 872 patients with CD who were exposed to the first biological therapy at Samsung Medical Center between 1995 and 2020 is presented. V-CDST & U-CDST were calculated based on clinical and laboratory data immediately before the first biologic was initiated. The Cumulative Link Mixed Model (CLMM) test, weighted Kappa and plot, and Spearman’s correlation was used to determine the degree of agreement and difference between the two tools. 25% of all patients diagnosed with biologically naïve CD were categorized into different probability groups using V-CDST and U-CDST. The difference between the two tools was significantly based on a two-sample paired ordinal test with Cumulative Link Mixed Model (CLMM) (p-value < .001). Concordance between the two tools with a total of 654 subjects (75% of all patients) showed a similar probability (weighted Kappa: 0.47, 95% CI: 0.41–0.52). V-CDST and U-CDST are useful in selecting vedolizumab or ustekinumab in 25% of biologically naïve CD patients in our hypothetical scenario.

Supplemental Digital Content is available in the text, The prognosis of early-onset sporadic colorectal cancer (CRC) patients remains controversial. The objective of this study was to assess the long-term outcome and prognostic factors of sporadic CRC in young patients. From 2006 to 2011, 8207 patients underwent curative or palliative surgery for CRCs in our institution. A total of 693 patients who were ≤45 years old with sporadic CRC were enrolled as the young group. A total of 1823 patients aged between 56 and 65 years were identified as middle-aged control group for this study. Survival outcome and prognostic factors were compared between the two groups. Young patients had higher recurrence rate than older patients in stages I and II (8.8% vs 2.7%, P